Immune Therapeutics Stock Current Valuation
| IMUNDelisted Stock | USD 0.06 0 4.76% |
Valuation analysis of Immune Therapeutics helps investors to measure Immune Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Immune Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Immune Therapeutics is based on 3 months time horizon. Increasing Immune Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Immune Therapeutics is useful when determining the fair value of the Immune pink sheet, which is usually determined by what a typical buyer is willing to pay for full or partial control of Immune Therapeutics. Since Immune Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Immune Pink Sheet. However, Immune Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.06 | Real 0.0595 | Hype 0.06 |
The real value of Immune Pink Sheet, also known as its intrinsic value, is the underlying worth of Immune Therapeutics Company, which is reflected in its stock price. It is based on Immune Therapeutics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Immune Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Immune Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Immune Therapeutics helps investors to forecast how Immune pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Immune Therapeutics more accurately as focusing exclusively on Immune Therapeutics' fundamentals will not take into account other important factors: Immune Therapeutics Company Current Valuation Analysis
Immune Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Immune Therapeutics Current Valuation | 83.25 M |
Most of Immune Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immune Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Immune Therapeutics has a Current Valuation of 83.25 M. This is 99.42% lower than that of the Biotechnology sector and 98.21% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.5% higher than that of the company.
Immune Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immune Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Immune Therapeutics could also be used in its relative valuation, which is a method of valuing Immune Therapeutics by comparing valuation metrics of similar companies.Immune Therapeutics is currently under evaluation in current valuation category among related companies.
Immune Fundamentals
| Return On Asset | -0.45 | |||
| Current Valuation | 83.25 M | |||
| Shares Outstanding | 82.76 M | |||
| Shares Owned By Insiders | 29.51 % | |||
| Price To Earning | 333.33 X | |||
| Price To Sales | 161.50 X | |||
| Gross Profit | 65.83 K | |||
| EBITDA | 3.8 M | |||
| Net Income | 3.59 M | |||
| Cash And Equivalents | 271.53 K | |||
| Total Debt | 1.08 M | |||
| Debt To Equity | 1.97 % | |||
| Current Ratio | 0.04 X | |||
| Book Value Per Share | (0.03) X | |||
| Cash Flow From Operations | (231.72 K) | |||
| Earnings Per Share | 0.03 X | |||
| Number Of Employees | 15 | |||
| Beta | 0.52 | |||
| Market Capitalization | 39.1 M | |||
| Total Asset | 3.14 M | |||
| Retained Earnings | (319.86 M) | |||
| Working Capital | (7.47 M) | |||
| Current Asset | 22 K | |||
| Current Liabilities | 7.49 M | |||
| Net Asset | 3.14 M |
About Immune Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immune Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immune Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immune Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immune Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immune Therapeutics' short interest history, or implied volatility extrapolated from Immune Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Immune Pink Sheet
If you are still planning to invest in Immune Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Therapeutics' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |